STABILISIERUNG VON K1K2P PRO

摘要

The invention relates to a pharmaceutical preparation of a non-glycosylized t-PA derivative, K1K2P pro, with an enzymatic activity of at least 0.4 MU/ml and a pH of 4.5 to 6, containing citrate and at least one compound from the following group: a) ascorbic acid, b) EDTA, c) amino compounds of formula R<1>R<2>N -R - X, where X = SO3H, CH(NH2)-CO2H, CO2H, H, NH2 or OH, R = C1-C9 alkylene, C3-C6 cycloalkylene or benzylidene and R<1> and R<2>, independently of each other, are H or C1-C3 alkyl, d) guianidinobutyric acid, e) dimethylbiguanide, f) arginine, g) glucosamine, fructose, h) pyrimidine nucleosides and pyrimidine nucleotides, i) carboxylic acids substituted with one or more hydroxyl, keto and/or further carboxyl groups. The invention also relates to a drug containing the t-PA derivative K1K2P pro as the active ingredient and a process for producing it.